<DOC>
	<DOCNO>NCT01192191</DOCNO>
	<brief_summary>The primary purpose study evaluate safety tolerability fluticasone furoate/GW642444 inhalation powder administer once-daily 52 week Japanese patient COPD .</brief_summary>
	<brief_title>A Long-term Safety Study Fluticasone Furoate ( FF ) /GW642444 Japanese Subjects With COPD</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Out patient least 40 year age Both gender ; female childbearing potencial must willing use birth control method A diagnosis COPD Screening Subjects current prior history least 10 packyears cigarett smoke Screening Postbronchodilator FEV1/FVC ratio le 70 % Postbronchodilator FEV1 le 80 % Current diagnosis sthma Respiratory disorder COPD Upper low respiratory infection , exacerbation COPD within 4 weeka prior Screening Concurrent disease would confound study participation affect subject safety Allergies study drug , study drug ' excipients , medication relate study drug Taking another investigational medication medication prohibit use study</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>GW642444</keyword>
	<keyword>COPD</keyword>
	<keyword>Fluticasone Furoate</keyword>
</DOC>